- Home
- AMGN vs BTI Comparison
AMGN vs BTI Comparison
Compare AMGN & BTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- BTI
- Stock Information
- Founded
- AMGN 1980
- BTI 1902
- Country
- AMGN United States
- BTI United Kingdom
- Employees
- AMGN N/A
- BTI N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- BTI Medicinal Chemicals and Botanical Products
- Sector
- AMGN Health Care
- BTI Health Care
- Exchange
- AMGN Nasdaq
- BTI Nasdaq
- Market Cap
- AMGN 156.3B
- BTI 125.1B
- IPO Year
- AMGN N/A
- BTI N/A
- Fundamental
- Price
- AMGN $287.44
- BTI $56.89
- Analyst Decision
- AMGN Hold
- BTI Strong Buy
- Analyst Count
- AMGN 18
- BTI 2
- Target Price
- AMGN $320.11
- BTI N/A
- AVG Volume (30 Days)
- AMGN 2.0M
- BTI 4.5M
- Earning Date
- AMGN 10-29-2025
- BTI 09-15-2025
- Dividend Yield
- AMGN 3.31%
- BTI 5.37%
- EPS Growth
- AMGN 110.88
- BTI N/A
- EPS
- AMGN 12.23
- BTI 1.89
- Revenue
- AMGN $34,917,000,000.00
- BTI $35,067,817,512.00
- Revenue This Year
- AMGN $8.99
- BTI N/A
- Revenue Next Year
- AMGN $1.79
- BTI $3.06
- P/E Ratio
- AMGN $23.52
- BTI $29.58
- Revenue Growth
- AMGN 12.88
- BTI N/A
- 52 Week Low
- AMGN $253.30
- BTI $34.17
- 52 Week High
- AMGN $339.17
- BTI $59.29
- Technical
- Relative Strength Index (RSI)
- AMGN 42.02
- BTI 56.08
- Support Level
- AMGN $284.87
- BTI $55.69
- Resistance Level
- AMGN $290.25
- BTI $59.29
- Average True Range (ATR)
- AMGN 4.52
- BTI 0.67
- MACD
- AMGN -0.74
- BTI -0.43
- Stochastic Oscillator
- AMGN 18.02
- BTI 33.33
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About BTI British American Tobacco Industries p.l.c. ADR
The third-largest tobacco company by volume, British American Tobacco sold 518 billion cigarettes in 2024. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the US. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 22.9% stake in ITC limited, the largest Indian cigarette company.